Skye Bioscience, Inc. (SKYE)
| Previous close | 14.81 |
| Open | 15.50 |
| Bid | 13.72 x 100 |
| Ask | 14.60 x 100 |
| Day's range | 13.65 - 15.60 |
| 52-week range | 1.44 - 19.41 |
| Volume | |
| Avg. volume | 39,766 |
| Market cap | 397.651M |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.37 |
| Earnings date | 12 May 2024 - 16 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.50 |
GlobeNewswireSkye Bioscience to Present at Upcoming Investment Conferences
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair Punit Dhillon and other members of Skye’s executive team will present the company and its programs in obesity and glaucoma at the following investment conferences: Conference
- GlobeNewswire
Skye Bioscience Uplists to The Nasdaq Global Market
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global Market® stock exchange ("Nasdaq"). The Company's common sto
- GlobeNewswire
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with a focus on obesity and ocular indications, is pleased to announce the appointment of Dr. Annalisa Jenkins, MBBS, FRCP, to the Company’s Board of Directors. Dr. Jenkins’ esteemed career spans more than 25 yea
